回盛生物(300871) - 2025 Q4 - 年度业绩预告

Financial Performance Forecast - The company expects a net profit of approximately 235 million yuan for the year 2025, representing a significant increase of 1,265.93% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses is projected to be around 212.5 million yuan, reflecting a growth of 1,408.61% year-over-year[4] - The increase in net profit is primarily driven by revenue growth from both domestic and international markets, along with improvements in production capacity and rising raw material prices[6] - The performance forecast indicates a turnaround from previous losses, marking a significant recovery for the company[3] Non-Recurring Gains and Losses - The company anticipates that non-recurring gains and losses will impact net profit by approximately 22.5 million yuan during the reporting period[7] Financial Data and Audit - The financial data presented is based on preliminary estimates by the company's finance department and has not yet been audited by the accounting firm[5] - The company has communicated with the accounting firm regarding the performance forecast, and there are no significant discrepancies between the two parties[5] - The company plans to disclose detailed financial data in the 2025 annual report[8] Market Expansion and Cost Management - The company has successfully reduced financial expenses due to the early redemption of convertible bonds during the reporting period[7] - The company is actively expanding its market presence both domestically and internationally, contributing to revenue growth[6]